A phase 1/2, partially randomized, open-label study of visilizumab in patients with severe ulcerative colitis refractory to intravenous corticosteroids.

Trial Profile

A phase 1/2, partially randomized, open-label study of visilizumab in patients with severe ulcerative colitis refractory to intravenous corticosteroids.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2012

At a glance

  • Drugs Visilizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PDL BioPharma
  • Most Recent Events

    • 08 Mar 2012 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
    • 01 Apr 2010 Results published in Inflammatory Bowel Disease.
    • 26 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top